On this page
Study design
The JAMA analysis pooled six selected observational and clinical-trial cohorts, following 2,684 adults who were cognitively unimpaired when their blood was sampled. Researchers related baseline plasma p-tau217 to later cognitive impairment and change on a cognitive composite; median follow-up was 5.4 years.
What it found
Each standard-deviation increase in p-tau217 was associated with a higher rate of progression. Modelled absolute risk in the very-high group was 38% over five years and 78% over ten years, compared with 12% and 40% in the low group. The study estimates association and risk within these cohorts.
Limits and interpretation
Ten-year estimates had wider uncertainty because fewer participants remained under observation that long. The cohorts were selected research samples, so estimates may not transfer directly to the general population or an individual. The paper supports further validation of prognostic models; it does not establish that biomarker testing or treatment changes outcomes in symptom-free people.
This sourced news summary and translation were prepared with AI assistance. Source links, the news date and research limitations are disclosed; this is not a claim of independent medical expert review. News production method.
Sources
Research news is not medical advice or a recommendation to use a substance. Read findings in the context of the study design, participants and limitations. Editorial standards.
← All news